Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | Critical Care

Figure 3

From: Cost-effectiveness of activated protein C in real-life clinical practice

Figure 3

Cost-effectiveness acceptability curves of rhAPC. The curves represent the probability that treatment with recombinant human activated protein C (rhAPC) is associated with a cost per life-year gained and a cost per quality-adjusted life-years (QALY) gained that are lower than the corresponding incremental cost-effectiveness ratios shown on the x-axis. There was a 74.5% probability that the use of rhAPC would be cost-effective if there were willingness to pay €50,000 per life-year gained and a 64.3% probability if there were willingness to pay €50,000 per QALY gained.

Back to article page